Circe Biomedical, Inc.

Rhode Island Hospital

Sharda Naik

Hugo O Jauregui

Donna M Trenkler

Timothy Jon Perlman

Shawn P Cain

Claudy Jean-Paul Mullon

Henry A Santangini

Henry Santangini

An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99%. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.

Method of cryopreserving hepatocytes

A perfusion device such as a liver assist device containing a housing defining a perfusion inlet and a perfusion outlet, a porous membrane structure mounted within said housing to define a perfusion compartment and an adjacent hepatocyte compartment, and porcine hepatocytes isolated from a porcine liver by retrograde perfusion.

Isolation and culture of porcine hepatocytes

An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99% and a metabolic activity 50-80% of fresh hepatocytes. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.

Cryopreserved hepatocytes and high viability and metabolic activity

Growing community of inventors

Cranston, RI, United States of America

Sharda Naik